Sign up to save your podcasts
Or
Share AI in Oncology: Building Smarter Clinical Trials and Closing Data Gaps
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
AI in Oncology: Building Smarter Clinical Trials and Closing Data Gaps
In this episode of MD Newsline, Dr. Arsela Prelaj, a thoracic oncologist and AI researcher at the Istituto Nazionale dei Tumori in Milan, Italy, explores the rapidly evolving role of artificial intelligence in oncology. Drawing from her background in medical oncology and bioengineering, Dr. Prelaj discusses how AI is revolutionizing clinical trial design, improving trial success rates, and expanding patient access to innovative therapies.
She shares real-world examples of how machine learning, large language models, and synthetic data are being integrated into cancer research, while also addressing ethical considerations, data fairness, and the future of AI-driven decision-making in medicine.
Episode HighlightsAI in Clinical Trial Design and Drug Development Dr. Prelaj explains how AI tools are dramatically improving success rates in early-phase clinical trials. Technologies such as AlphaFold and predictive modeling are helping researchers identify promising drug targets, reduce trial failures, and optimize trial design before patients are enrolled.
Predicting Trial Success and Reducing Failure AI-powered platforms can analyze historical clinical trial data to forecast the likelihood of success in Phase I, II, and III studies. Dr. Prelaj discusses how these insights benefit pharmaceutical companies, investigators, and ultimately patients by reducing exposure to ineffective treatments.
Virtual Trials and Real-World Data Integration The conversation explores how virtual and pragmatic trial models leverage real-world data to simulate outcomes, relax restrictive inclusion criteria, and make trials more accessible to diverse patient populations—without compromising scientific rigor.
Clinical Trial Matching and Physician Efficiency Dr. Prelaj highlights AI-driven clinical trial matching tools that can reduce physician workload by nearly 50%, helping clinicians quickly identify the most appropriate trials for individual patients while prioritizing those with the greatest potential benefit.
Patient Advocacy and AI-Powered Access to Trials AI is empowering patients to actively participate in their care. Dr. Prelaj discusses patient-facing tools that allow individuals to identify relevant trials, initiate informed conversations with physicians, and advocate for access to cutting-edge treatments.
Data Democratization, Bias, and Fairness The episode addresses critical challenges surrounding data governance, paywalled research, and underrepresentation in clinical trials. Dr. Prelaj explains how synthetic data and fairness auditing can help reduce disparities across race, ethnicity, and rare disease populations.
The Future of AI in Oncology: Agents and Digital Twins Looking ahead, Dr. Prelaj shares her excitement about AI agents and digital twin models—dynamic systems that mirror real patients over time to support clinical decision-making, personalize treatment strategies, and enhance precision oncology.
Key TakeawayDr. Prelaj emphasizes that artificial intelligence is not replacing clinicians—but augmenting their expertise. By combining AI-driven insights with human judgment, oncology is entering a new era of smarter trials, more equitable care, and data-informed decision-making that has the potential to improve outcomes for patients worldwide.
ResourcesWebsite: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/
Connect with Dr. Arsela Prelaj: Here
View all episodes
By MD NewslineIn this episode of MD Newsline, Dr. Arsela Prelaj, a thoracic oncologist and AI researcher at the Istituto Nazionale dei Tumori in Milan, Italy, explores the rapidly evolving role of artificial intelligence in oncology. Drawing from her background in medical oncology and bioengineering, Dr. Prelaj discusses how AI is revolutionizing clinical trial design, improving trial success rates, and expanding patient access to innovative therapies.
She shares real-world examples of how machine learning, large language models, and synthetic data are being integrated into cancer research, while also addressing ethical considerations, data fairness, and the future of AI-driven decision-making in medicine.
Episode HighlightsAI in Clinical Trial Design and Drug Development Dr. Prelaj explains how AI tools are dramatically improving success rates in early-phase clinical trials. Technologies such as AlphaFold and predictive modeling are helping researchers identify promising drug targets, reduce trial failures, and optimize trial design before patients are enrolled.
Predicting Trial Success and Reducing Failure AI-powered platforms can analyze historical clinical trial data to forecast the likelihood of success in Phase I, II, and III studies. Dr. Prelaj discusses how these insights benefit pharmaceutical companies, investigators, and ultimately patients by reducing exposure to ineffective treatments.
Virtual Trials and Real-World Data Integration The conversation explores how virtual and pragmatic trial models leverage real-world data to simulate outcomes, relax restrictive inclusion criteria, and make trials more accessible to diverse patient populations—without compromising scientific rigor.
Clinical Trial Matching and Physician Efficiency Dr. Prelaj highlights AI-driven clinical trial matching tools that can reduce physician workload by nearly 50%, helping clinicians quickly identify the most appropriate trials for individual patients while prioritizing those with the greatest potential benefit.
Patient Advocacy and AI-Powered Access to Trials AI is empowering patients to actively participate in their care. Dr. Prelaj discusses patient-facing tools that allow individuals to identify relevant trials, initiate informed conversations with physicians, and advocate for access to cutting-edge treatments.
Data Democratization, Bias, and Fairness The episode addresses critical challenges surrounding data governance, paywalled research, and underrepresentation in clinical trials. Dr. Prelaj explains how synthetic data and fairness auditing can help reduce disparities across race, ethnicity, and rare disease populations.
The Future of AI in Oncology: Agents and Digital Twins Looking ahead, Dr. Prelaj shares her excitement about AI agents and digital twin models—dynamic systems that mirror real patients over time to support clinical decision-making, personalize treatment strategies, and enhance precision oncology.
Key TakeawayDr. Prelaj emphasizes that artificial intelligence is not replacing clinicians—but augmenting their expertise. By combining AI-driven insights with human judgment, oncology is entering a new era of smarter trials, more equitable care, and data-informed decision-making that has the potential to improve outcomes for patients worldwide.
ResourcesWebsite: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/
Connect with Dr. Arsela Prelaj: Here